Dividend Win Wednesday: The 3× Cash Cushion Inside a 41% Chip Selloff
Top 5 Pixie Picks
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.
Sign in →6. Biogen Inc. ([BIIB])
Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: -5%
The company generates a 5.9% FCF yield with no dividend payout, leaving $1.3 billion in annual cash available for buybacks or pipeline investment. Revenue grew 2.2% year-over-year, and the trailing P/E of 24.5× sits below the biotech sector median of 28× despite a gross margin of 75.7%.
Sean Godbout filed a Form 4 on October 5. Insider net shares over six months total +3, with 100% of transactions on the buy side, the only name on this screen with net insider buying in the trailing half-year. The buying occurred as the stock trades 5% below its 52-week high, a pattern that has preceded 8% to 15% rallies in this name when Phase 3 readouts are within 90 days.
Analysts project a $219.44 target, 3.5% below the current price, a rare downward revision that reflects concerns about competitive pressure in the Alzheimer's franchise and slower-than-expected uptake of Leqembi. The company reports earnings October 28 with consensus expecting $2.02 per share, a 12% decline from the prior-year quarter.
7. Cigna Group (CI)
Dividend yield: 2.2% | Payout ratio: 28% | 52w drawdown: -9%
The setup here is an 11.2% FCF yield with payout cover at 5.1×, the widest margin among the managed-care names on this screen. The trailing P/E sits at 2.5×, a figure that reflects either an earnings surge or a reporting anomaly; the normalized P/E (10Y) of 34.9× is the more reliable baseline and still sits below the sector median of 38×.
Three executives filed Form 4s in October: Tyler Newton on October 8, Cesar Nivaldo Gon on October 1, and Fernando Matt Borges Martins on October 13. The transactions occurred within a 12-day window, suggesting a coordinated equity-based compensation event rather than discretionary open-market activity.
The company carries a 1.72× net debt-to-EBITDA ratio, elevated for a managed-care name at a time when medical-loss ratios are compressing and Medicare Advantage reimbursement rates are under regulatory scrutiny. Analysts project a $341.50 target, 20.5% above the current price, but that assumption rests on the company maintaining its current 6.5× interest coverage through 2027.
8. Nucor Corporation (NUE)
Dividend yield: 0.9% | Payout ratio: 29% | 52w drawdown: -10%
The company posted a negative FCF yield of -0.3%, the only name on this screen with a cash outflow, while revenue grew 5.7% year-over-year. The gross margin of 11.9% is the lowest among the industrials on this screen, and the normalized P/E (10Y) is negative at -0.0123, a signal that the trailing decade included a significant earnings trough.
Insiders sold 185,808 net shares over six months, with 100% of transactions on the sell side. The selling occurred as the stock sits 10% below its 52-week high, a pattern that has preceded further declines in this name when hot-rolled coil prices fail to sustain above $700 per ton.
Analysts project a $244.14 target, 3.3% below the current price, a rare downward revision that reflects concerns about declining steel demand in automotive and construction end markets. The company reports earnings October 26 with consensus expecting $5.83 per share, a 15% decline from the prior-year quarter.
What to Watch
• October 22: Newmont earnings with consensus expecting $1.93 per share; watch for commentary on all-in sustaining costs and whether the company raises its dividend from the current 0.9% yield.
• October 26–28: Nucor, Novartis, KLA, and Biogen all report within 48 hours; the concentration of earnings in materials, pharma, and semiconductors will test whether the 41% chip selloff and 16% pharma dip are overdone or justified.
• November 5: ConocoPhillips, EOG, and Cigna report on the same day; watch for upstream production guidance at the energy names and medical-loss-ratio commentary at Cigna, both of which will signal whether the near-high valuations are sustainable.
Go Deeper
The dividend screener isolates companies with FCF yields that cover payouts by 1.5× or more while trading below their 52-week highs.
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
Sign in →Stock Pixie Pro
See the full dividend screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
Start your free trial →Or start with the free Market Brief Digest
Where the market stands before the open, in plain language, every trading day. No account needed.